Brief: Prostatype Genomics Says Running Costs Are Reduced By About 30% (Approx Sek 9 Million On An Annual Basis) Without Affecting Sales And Continued Research.
30/10/2023 16:54
Oct 30 (Reuters) - Prostatype Genomics AB PROGEN.ST :
* PROSTATYPE GENOMICS - RUNNING COSTS ARE REDUCED BY ABOUT
30%
(APPROX SEK 9 MILLION ON AN ANNUAL BASIS) WITHOUT AFFECTING
SALES AND CONTINUED RESEARCH.
Source text for Eikon: ID:nWkr8XH2SL
Further company coverage: PROGEN.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prostatype Genomics AB
See all newsBrief: Prostatype Genomics Cannot Specify Timing For Final Medicare Decision
Brief: Prostatype Genomics Enters SEK 6.0 Mln Agreement With Vator Securities For To6
Brief: Prostatype Genomics AB H1 2026 Net Sales SEK 457,000
Brief: Prostatype Genomics Resolves On Directed Issue
Brief: Prostatype Genomics To Receive About SEK 47.4 Mln From Rights Issue